Pfizer and BioNTech's COVID-19-Flu Vaccine Faces Setback with 2.4% Decline

Aug 16, 2024, 01:30 PM

Pfizer and BioNTech have updated their mRNA-based combination vaccine program against influenza and COVID-19 for individuals aged 18-64. The COVID-19-flu combination drug met one of two trial objectives, but showed a lower immune response against influenza B. This setback in their late-stage trial has resulted in a 2.4% pre-market decline in BioNTech's stock. The combination vaccine's partial success highlights ongoing challenges in developing effective vaccines against multiple strains.